Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionEnvestnet Asset Management Inc
Latest Disclosed Ownership171,797 shares
Latest Disclosed Value $ 56,842,551
Envestnet Asset Management Inc reports 42.55% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 4, 2026 - Envestnet Asset Management Inc filed a 13F-HR form disclosing ownership of 171,797 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $49,082,403 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 120,521 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 42.55% during the quarter. The current value of the position is $44,753,118 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 171,797 51,276 42.55 56,843 18.61 0.0152
2026-02-10 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 120,521 1,557 1.31 47,925 -11.66 0.0142
2025-11-05 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 118,964 23,168 24.18 54,248 73.66 0.0156
2025-08-01 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 95,796 23,749 32.96 31,238 60.57 0.0091
2025-04-29 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 72,047 6,033 9.14 19,454 25.24 0.0063
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,014 34,647 110.46 15,534 80.07 0.0050
2024-11-07 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,367 6,227 24.77 8,627 41.20 0.0028
2024-08-08 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,140 -2,295 -8.37 6,109 49.00 0.0021
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,435 156 0.57 4,100 -21.47 0.0015
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,279 2,709 11.03 5,221 20.00 0.0022
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,570 5,727 30.39 4,351 21.60 0.0020
2023-08-04 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,843 3,477 22.63 3,579 16.24 0.0016
2023-05-11 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,366 1,280 9.09 3,078 -8.04 0.0015
2023-02-07 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,086 -3,000 -17.56 3,348 -2.13 0.0017
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,086 2,972 21.06 3,420 66.10 0.0020
2022-08-03 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,114 -17,306 -55.08 2,059 -59.87 0.0012
2022-05-04 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,420 -2,893 -8.43 5,131 -11.82 0.0026
2022-02-04 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,313 2,828 8.98 5,819 -2.10 0.0029
2021-10-07 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,485 1,480 4.93 5,944 16.87 0.0033
2021-08-04 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,005 3,378 12.69 5,086 35.30 0.0029
2021-05-04 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,627 12,998 95.37 3,759 112.25 0.0024
2021-02-02 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,629 -24,953 -64.68 1,771 -68.48 0.0013
2020-10-09 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,582 -1,758 -4.36 5,618 -5.97 0.0050
2020-07-08 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,340 31,940 380.24 5,975 553.72 0.0058
2020-04-23 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,400 8,400 914 0.0011
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.